Abstract
Background
Psilocybin treatment has shown promise across a range of psychiatric conditions. Mystical-type experiences during dosing sessions have been shown to predict the clinical effects of psilocybin treatment in depression, anxiety, and addiction. However, no studies have examined whether acute subjective experiences predict treatment response in obsessive-compulsive disorder (OCD).
Methods
Exploratory analyses were conducted using data from participants with treatment-resistant OCD who received psilocybin as part of a randomized, double-blind, placebo-controlled trial and subsequent open-label phase. Twenty-seven participants who received psilocybin (0.25 mg/kg) completed the Mystical Experience Questionnaire (MEQ-30) and Challenging Experience Questionnaire (CEQ) the day following their session. OCD severity was assessed using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) at baseline and at 1- and 12-week follow-up.
Results
Greater mystical-type experiences during psilocybin were associated with lower OCD symptom severity at 1- and 12-week follow-up, even after controlling for baseline OCD symptom severity and treatment condition. The Mystical subscale demonstrated the strongest and most consistent associations at both time points, while the Space–Time subscale was only associated with lower Y-BOCS at 12 weeks. The Positive Mood and Ineffability subscales were not significantly associated with post-treatment OCD symptom severity after correction for multiple comparisons. Challenging experiences were not significantly associated with post-treatment OCD severity.
Conclusions
Mystical experiences – particularly experiences of unity, sacredness, and transcendence – during psilocybin sessions are associated with greater OCD symptom reduction. These findings support attention to experiential quality in psilocybin-assisted therapy and have implications for optimizing treatment through dosing, set, setting, and integration practices.
Keywords: acute effects, challenging experience, clinical trial, mystical experience, obsessive-compulsive disorder, psilocybin, psychedelic, treatment response
1. Introduction
Obsessive–compulsive disorder (OCD) is a chronic and often debilitating psychiatric condition (1). Although first-line treatments, including selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT) with exposure and response prevention, are effective for many patients (2), a significant proportion remain symptomatic despite adequate trial (3, 4), and clinically significant effects typically take months to achieve (5, 6). Novel therapeutic approaches are urgently needed.
In recent years, psilocybin—a naturally occurring psychedelic compound and 5-HT2A agonist that can produce profound alterations in perception, cognition, and emotion (7, 8)—has re-emerged as a promising treatment for a range of mental health conditions (9, 10). Psychedelic-assisted therapy commonly involves administering these compounds in controlled settings with structured psychological support, aiming to facilitate meaningful therapeutic experiences (11). Research has demonstrated the therapeutic potential of psilocybin in alleviating depression (12), end-of-life anxiety (13), and substance use disorders (14).
Our group recently completed a randomized, double-blind, placebo-controlled trial of psilocybin with non-directive support for treatment-resistant OCD (15). At the primary endpoint, participants in the psilocybin group demonstrated significantly larger reductions in OCD symptoms than those in the placebo group. However, treatment response was heterogeneous: approximately half of the participants experienced substantial and rapid symptom relief, whereas others showed minimal change. Additionally, a recent randomized clinical trial of repeated psilocybin dosing for OCD similarly found that psilocybin was generally well tolerated and associated with reductions in OCD severity, further supporting clinical interest in psilocybin as a potential intervention for OCD while underscoring the need for larger trials (16). These findings provide preliminary support for the efficacy of psilocybin-assisted therapy in OCD, and – as in the case of established treatments for OCD – highlight marked variability in treatment response. Understanding the sources of this variability is critical for optimizing treatment outcomes.
Emerging evidence suggests that psilocybin may enhance cognitive flexibility and reduce rigid, perseverative thinking patterns characteristic of OCD (17–19). Neuroimaging studies indicate that psilocybin decreases activity and connectivity within the default mode network (DMN) (20, 21), which has been implicated in excessive self-referential processing and rumination in OCD (22–24), Furthermore, the mystical experience—characterized by ego dissolution (25) and a sense of interconnectedness (26)—may directly counteract the intolerance of uncertainty and need for control that are central to OCD psychopathology (27, 28). These considerations provide a theoretical basis for examining whether mystical experiences during psilocybin sessions are associated with therapeutic response in OCD.
Psychedelic sessions at sufficient doses often induce “peak” experiences described as mystical or transcendent—characterized by a sense of unity or oneness, ego dissolution, transcendence of time and space, sacredness, positive mood, and ineffability. Mystical-type experiences have been quantified in the research literature using several self-report instruments, among which the Mystical Experience Questionnaire (MEQ-30) (26) has emerged as the most widely adopted measure. Accumulating evidence indicates that the intensity of mystical experiences during psilocybin sessions is positively associated with clinical improvements across multiple studies and patient populations (29).
Two randomized controlled trials in cancer patients showed that a single high-dose psilocybin session led to rapid and sustained reductions in anxiety and depression, with mystical experience intensity predicting and mediating treatment effects (30, 31). Similar findings have emerged in substance use disorder research. Among smokers receiving psilocybin treatment, those who achieved abstinence at 6 months scored significantly higher on measures of in-session mystical experience than those who continued smoking (32). Another study found that the magnitude of “oceanic boundlessness”—a construct sharing core features with mystical experiences—during psilocybin sessions significantly predicted reductions in depressive symptoms at five-week follow-up (33). Taken together, these findings suggest that a profound mystical-type experience may be a candidate process underlying therapeutic efficacy of psilocybin-assisted therapy.
Psychedelics can also provoke periods of intense fear, confusion, or emotional struggle—commonly described as “bad trips” or challenging experiences rather than uniformly negative or maladaptive states. The Challenging Experience Questionnaire (CEQ) was developed to quantify such difficult aspects (e.g., fear, grief, physical distress, paranoia) of the psychedelic experience (34). The role of challenging experiences in treatment outcome is complex. Some studies and anecdotal accounts indicate that working through challenging experiences can contribute to positive change, with users often later valuing these difficult moments for the insights or emotional breakthroughs that follow (35). In these cases, confronting fear or other negative emotions during the session, especially with proper support, may help resolve psychological conflicts and ultimately improve well-being (35, 36). However, severe challenging experiences also carry risks; they can be overwhelming and, if not skillfully managed, might lead to lasting distress or setbacks rather than therapeutic gain (36). Thus, it remains unclear to what extent challenging psychedelic experiences hinder or support clinical outcomes. This likely depends on factors such as the intensity of the challenge, the individual’s ability to cope or “surrender” to the experience, and the support/integration provided (37).
No published studies have examined the relevance of mystical or challenging experiences during psilocybin in the treatment of OCD. The present study investigated how acute subjective effects of psilocybin relate to subsequent OCD symptom severity. We hypothesized that higher mystical experience scores would be associated with greater symptom reduction, given the literature linking peak experiences to positive outcomes. The role of challenging experiences was explored without a firm a priori hypothesis.
2. Materials and methods
2.1. Participants
The present study is a secondary analysis of data from participants who received psilocybin (N = 28) as part of a phase 2, double-blind, randomized, placebo-controlled trial of psilocybin-assisted therapy for treatment-resistant OCD conducted at Yale University (15). Adults aged 18–65 with treatment-resistant OCD (≥2 failed adequate trials) and Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) scores ≥19 were enrolled; full eligibility criteria and baseline demographics are reported elsewhere (15). One participant was excluded due to missing data at the 1-week follow-up, resulting in a final sample of N = 27.
2.2. Procedures
Participants were randomized 1:1 to receive a single dose of psilocybin (0.25 mg/kg) or niacin placebo (250 mg) with standardized non-directive psychological support. Participants assigned to niacin were offered open-label psilocybin after completing week 1 assessments; all elected to cross over. Prior to dosing, participants completed two 90-minute preparation sessions. The 6- to 8-hour dosing session was conducted under continuous monitoring by two trained facilitators; participants wore eye shades and listened to a standardized music playlist. Four 90-minute integration sessions were completed post-dosing. Data were pooled across randomized and open-label arms to maximize sample size for these exploratory analyses. Treatment condition (blinded vs. open-label) was included as a covariate in all analyses to statistically control for potential differences between study phases, including expectancy effects associated with unblinded administration.
OCD symptom severity was measured at baseline (1 day prior to dosing, 1 week, and 12 weeks post-dosing. Acute subjective experiences during the dosing session were assessed the day following psilocybin session. Data on OCD symptom severity and acute subjective experiences were compiled from the randomized and open-label study arms.
2.3. Measures
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). The Y-BOCS (38) is a 10-item clinician-administered scale assessing obsession and compulsion severity over the past week. Items are rated 0–4, yielding a total score of 0–40, with higher scores indicating greater severity. The Y-BOCS is the gold-standard measure of OCD symptom severity and was administered at baseline, 1-week, and 12-weeks post-dosing.
Mystical Experience Questionnaire (MEQ-30). The MEQ-30 (26) is a 30-item self-report measure assessing mystical-type experiences occasioned by psychedelics. Items are rated on a 6-point scale (0 = none, not at all; 5 = extreme). The measure yields a total score and four subscale scores: Mystical (15 items; feelings of unity, sacredness, and noetic quality), Positive Mood (6 items), Transcendence of Time and Space (6 items), and Ineffability (3 items). The MEQ-30 was administered the day following the psilocybin session (randomized psilocybin or subsequent open-label psilocybin session for participants initially assigned to placebo).
Challenging Experience Questionnaire (CEQ). The CEQ (34) is a 26-item self-report measure assessing difficult or distressing aspects of psychedelic experiences, including fear, grief, physical distress, insanity, isolation, death, and paranoia. Items are rated on a 6-point scale (0 = none, not at all; 5 = extreme), with higher scores indicating more challenging experiences. The CEQ was administered the day following the psilocybin session (randomized psilocybin or subsequent open-label psilocybin session for participants initially assigned to placebo). CEQ scores were positively associated with ratings of meaning and spiritual significance, constructs closely related to MEQ-30 mystical experience.
2.4. Data analytic strategy
All statistical analyses and visualizations were conducted in RStudio (version 4.5.2). Bivariate Pearson correlations were first computed to examine whether baseline OCD severity (Y-BOCS) was associated with the intensity of acute mystical or challenging experiences. Associations between acute subjective experiences during psilocybin administration and OCD symptom severity (1- and 12-weeks post-treatment) were first examined using partial correlation analyses, controlling for baseline Y-BOCS scores and treatment condition (blinded vs. open-label). Partial correlations were computed for MEQ-30 total scores, MEQ-30 subscales, CEQ total scores, and CEQ subscales. Visualizations of significant and null associations were generated using partial regression plots in which both predictor and outcome variables were residualized with respect to baseline Y-BOCS and treatment condition. To account for multiple comparisons, Benjamini–Hochberg false discovery rate (FDR) (39) corrections were applied within each time point across all tested partial correlations. These FDR-corrected partial correlations served as the primary inferential analyses, given the modest sample size and the exploratory nature of examining multiple experiential dimensions.
As a secondary, exploratory analytic step, multiple linear regression models were planned for experiential measures that demonstrated statistically significant associations with post-treatment Y-BOCS outcomes in the primary partial correlation analyses. For measures meeting this criterion, regression models were estimated to examine associations with post-treatment Y-BOCS while controlling for baseline Y-BOCS and treatment condition. These regression analyses were conducted to provide a complementary presentation of the partial correlation results and to facilitate effect size interpretation (noting that standardized effects are equivalent to the corresponding partial correlations), rather than as independent hypothesis tests, Regression models were implemented using JT Tools (40), sjPlot (41), and broom (42) packages.
3. Results
Baseline OCD severity was not significantly correlated with mystical experiences (r = −.17, p = .39) or challenging experiences (r = .07, p = .74). MEQ-30-Total scores showed significant negative partial correlations with Y-BOCS at both 1-week (r = −0.535, p <.01) and 12-week follow-ups (r = −0.481, p <.05; Table 1A). Among MEQ-30 subscales, the Mystical subscale demonstrated the strongest associations with post-treatment OCD symptom severity, exhibiting significant negative partial correlations with Y-BOCS at both 1-week (r = −0.606, p <.01) and 12-weeks (r = −0.501, p <.05). The Space–Time subscale also showed a significant negative association with Y-BOCS at 12-weeks (r = −0.424, p <.05). Positive Mood and Ineffability subscales were not significantly associated with 1- or 12-week post-treatment Y-BOCS scores. No CEQ subscales were significantly associated with Y-BOCS at either time point (Table 1B). Reported p-values reflect Benjamini–Hochberg FDR correction applied within each time point across tested partial correlations.
Table 1.
Partial Correlations between acute subjective experience measures and post-treatment ocd severity (controlling for baseline severity and treatment condition).
| A. Partial correlations between MEQ-30 subscales and Y-BOCS outcomes. | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Week 1 Y-BOCS | Week 12 Y-BOCS | MEQ-30 total | MEQ-30 mystical | MEQ-30 positive mood | MEQ-30 space time | MEQ-30 ineffability | |||
| Week 1 Y-BOCS | 1.000 | |||||||||
| Week 12 Y-BOCS | 0.904*** | 1.000 | ||||||||
| MEQ-30 Total | −0.535** | −0.481* | 1.000 | |||||||
| MEQ-30 Mystical | −0.606** | −0.501* | 0.936*** | 1.000 | ||||||
| MEQ-30 Positive Mood | −0.282 | −0.235 | 0.807*** | 0.630** | 1.000 | |||||
| MEQ-30 Space Time | −0.367† | −0.424* | 0.849*** | 0.676*** | 0.647** | 1.000 | ||||
| MEQ-30 Ineffability | −0.369† | −0.402† | 0.803*** | 0.662*** | 0.576** | 0.782*** | 1.000 | |||
| B. Partial correlations between CEQ subscales and Y-BOCS outcomes. | ||||||||||
| Variable | Week 1 Y-BOCS | Week 12 Y-BOCS | CEQ total | CEQ fear | CEQ grief | CEQ physical | CEQ insanity | CEQ isolation | CEQ death | CEQ paranoia |
| Week 1 Y-BOCS | 1.000 | |||||||||
| Week 12 Y-BOCS | 0.895*** | 1.000 | ||||||||
| CEQ Total | −0.007 | −0.155 | 1.000 | |||||||
| CEQ Fear | 0.095 | 0.069 | 0.803*** | 1.000 | ||||||
| CEQ Grief | −0.271 | −0.406 | 0.769*** | 0.379 | 1.000 | |||||
| CEQ Physical | 0.177 | 0.049 | 0.487† | 0.639** | 0.031 | 1.000 | ||||
| CEQ Insanity | 0.053 | −0.035 | 0.604* | 0.414 | 0.287 | 0.250 | 1.000 | |||
| CEQ Isolation | 0.148 | 0.026 | 0.638** | 0.267 | 0.604* | −0.108 | 0.411 | 1.000 | ||
| CEQ Death | −0.138 | −0.178 | 0.149 | −0.002 | 0.252 | −0.277 | 0.110 | −0.012 | 1.000 | |
| CEQ Paranoia | −0.148 | −0.228 | 0.435 | 0.234 | 0.244 | 0.262 | 0.277 | 0.398 | −0.117 | 1.000 |
Partial correlations control for baseline Y-BOCS score and treatment condition. P-values were adjusted for multiple comparisons using the Benjamini–Hochberg false discovery rate (FDR) procedure. Values are partial Pearson correlation coefficients (r).N = 25 (1A). N = 24 (1B). MEQ-30, Mystical Experiences Questionnaire; CEQ, Challenging Experiences Questionnaire; Y-BOCS, Yale-Brown Obsessive Compulsive Scale.
†p < .10. *p < .05. **p < .01. ***p < .001.
Challenging experiences were not significantly associated with post-treatment OCD severity. Partial correlations between CEQ-Total and Y-BOCS were near zero at 1-week (r = −0.007) and small and non-significant at 12-weeks (r = −0.155; Table 1B). None of the CEQ subscales showed significant partial correlations with Y-BOCS at either time point following FDR correction. These findings indicate that the intensity of challenging experiences during psilocybin was not related to subsequent OCD symptom outcomes. These findings indicate that the intensity of challenging experiences during psilocybin was not related to subsequent OCD symptom outcomes (Figure 1).
Figure 1.

Mystical, but not challenging, experiences were associated with lower Y-BOCS symptom severity at 1-week and 12-week follow-ups. Scatterplots depict partial regression relationships between MEQ-30-Total (purple) and CEQ-Total (blue) scores and residualized post-treatment Y-BOCS scores at 1 week (left) and 12 weeks (right), controlling for baseline Y-BOCS severity and treatment condition (blinded vs. open-label). Higher MEQ-30-Total scores were associated with significantly lower OCD symptom severity at follow-up, whereas CEQ-Total scores were not significantly associated with Y-BOCS outcomes. Shaded bands represent 95% confidence intervals. Note. Each line represents a separate partial correlation (not a combined model). Purple = MEQ-30 (Mystical Experiences Questionnaire); Blue = CEQ (Challenging Experiences Questionnaire). Both axes are residualized with respect to baseline Y-BOCS and treatment condition, such that slopes correspond to the partial correlations reported in Table 1. MEQ-30, Mystical Experiences Questionnaire; CEQ, Challenging Experiences Questionnaire; Y-BOCS, Yale-Brown Obsessive Compulsive Scale. Both MEQ-30-Total and CEQ-Total scores are mean item scores (0–5 scale).
4. Discussion
Retrospective reports of mystical experiences during psilocybin dosing sessions were prospectively associated with post-treatment OCD symptoms after controlling for baseline OCD symptom severity and treatment condition (randomized vs. open-label). Conversely, challenging experiences during dosing sessions were not significantly associated with post-treatment OCD symptom severity, though this null finding should be interpreted cautiously given the modest sample size. These findings suggest that specific qualitative dimensions of the acute subjective experience—particularly mystical-type features—rather than the intensity of distressing or challenging phenomenology, may be most relevant to therapeutic response in OCD.
When examining MEQ-30 subscales, the largest associations with post-treatment OCD symptom severity were observed for the mystical dimension, which reflects experiences of unity, sacredness, and noetic insight. In contrast, positive mood and ineffability showed weak or non-significant associations with post-treatment OCD symptom severity, whereas the Space–Time subscale demonstrated a moderate association at 12 weeks that did not survive correction for multiple comparisons This pattern mirrors prior psychedelic research indicating subscale-specific predictive validity of the MEQ-30, wherein mystical-type experiences—but not all phenomenological dimensions—are most consistently associated with enduring psychological and behavioral change. Specifically, mystical experiences have been shown to predict perceived spiritual significance and positive life changes, whereas perceptual or temporal alterations alone do not reliably demonstrate such associations (24, 43). It is possible that the mystical factor captures experiences reflecting maximal disruption of self-referential processing, whereas perceptual alterations or temporal distortions involve more intermediate-level changes, dissolution of self-boundaries may represent a psychological process that is uniquely relevant to symptom improvement (35).
One plausible mechanistic account is provided by the REBUS model, which posits that psychedelics weaken entrenched cognitive patterns, facilitating new learning and perspective-taking (44). For OCD patients, the ego dissolution, unity, and insight characteristics of mystical experiences may engage processes that disrupt rigid, overlearned self-referential loops underlying obsessional thinking, offering an experiential demonstration that intrusive thoughts are transient and need not dictate behavior.
The absence of a significant relationship between challenging experiences and post-treatment OCD symptom severity is notable, but should be interpreted with caution, as the study may have been underpowered to detect smaller effects. Prior research varies regarding the potential therapeutic (35, 36) or counter-therapeutic (33) nature of challenging experiences during psilocybin sessions. One interpretation of the null finding is that challenging experiences are not inherently impactful; their therapeutic relevance may depend on whether they are successfully processed, integrated, and imbued with meaning rather than on their intensity alone (33, 45). Commonly used acute experience measures—including the CEQ—index the presence of difficult content but do not directly assess resolution, meaning-making, or successful emotional processing. Some participants with elevated CEQ scores may have struggled without breakthrough, while others may have navigated challenges constructively—gains that would be reflected in their MEQ-30 rather than CEQ scores. This interpretation aligns with research suggesting that acceptance and “surrender” when navigating difficult psychedelic experiences, rather than resistance, facilitates emotional breakthrough and positive outcomes (33, 37). Thus, our findings highlight that mystical aspects of the experience are most consistently associated with clinical change, whereas the role of challenging experiences is likely more nuanced and contingent on context, coping strategies, and integration (35, 36). Future research should examine whether the integration of challenging material—rather than its raw intensity—contributes to clinical outcomes.
Qualitative data from a companion interpretative phenomenological analysis (46) provide further context for these findings. Participants frequently described “partial mystical experiences,” with OCD symptoms intruding upon and disrupting full immersion in the psychedelic state. However, those who reported approach behaviors—”letting go” or “surrendering” to arising experiences rather than resisting—described more positive outcomes. Notably, the qualitative analysis revealed that facilitator support was integral for some participants to navigate OCD-related distress during dosing without excessive maladaptive reactions (46). Many individuals with OCD characteristically exhibit a strong need for control and predictability (47), which may render them particularly vulnerable to distress when psychedelic effects intensify.
Several limitations should be acknowledged. The sample size was relatively small (N = 27) and racially/ethnically homogeneous, limiting statistical power and generalizability. Expectancy-related influences should also be considered: although part of the study employed randomization and placebo control, approximately half of the sample participated in an open-label psilocybin phase, and expectancy effects were likely present even during blinded conditions given the distinctive subjective effects of psilocybin. Participants may therefore have inferred treatment assignment, introducing potential expectancy effects. In addition, selection effects may have influenced the observed associations, as individuals predisposed to benefit from psilocybin may have been more likely to enroll in the study or to report more intense mystical-type experiences. Other potentially relevant acute processes (e.g., emotional breakthrough or specific insights) were not directly measured and may also contribute to post-treatment outcomes. Finally, follow-up was limited to 12 weeks, and whether these associations persist over longer intervals remains unknown.
In this study of psilocybin-assisted treatment for OCD, mystical-type experiences during dosing were associated with greater reductions in OCD symptom severity, whereas challenging experiences were not. This null finding should be interpreted cautiously given the small sample size and the CEQ’s limited ability to distinguish unresolved distress from difficult experiences that were constructively processed or integrated. Overall, mystical-type phenomenology showed the clearest association with symptom improvement, while the role of challenging experiences may be more context-dependent and nuanced.
Acknowledgments
The authors wish to thank past postgraduate assistants and research assistants for their efforts in project coordination.
Funding Statement
The author(s) declared that financial support was received for this work and/or its publication. This work for the primary study was supported by a grant from the Yale Center for Clinical Investigation (YCCI), grants from the Heffter Foundation and the Turnbull Family Foundation, and by the State of Connecticut through its support of the Ribicoff Research Facilities at the Connecticut Mental Health Center. The Usona Institute provided the investigational drug. The funding organizations were not involved in the design and conduct of this trial, and were not involved in the analysis, interpretation, or dissemination of the data.
Footnotes
Edited by: Jayne Morriss, University of Southampton, United Kingdom
Reviewed by: Hannah Berg, Laureate Institute for Brain Research, United States
Fauzah Rahimah Mohd Ali, International Islamic University Malaysia, Malaysia
Data availability statement
The datasets presented in this article are not readily available due to ethical and privacy considerations related to the small sample size and sensitive clinical content. De-identified data may be made available from the corresponding author upon reasonable request and with appropriate approvals.
Ethics statement
The studies involving humans were approved by Yale Human Research Protection Program (IRB). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
SS: Conceptualization, Investigation, Visualization, Data curation, Writing – review & editing, Formal analysis, Writing – original draft. GA-L: Writing – original draft, Supervision, Conceptualization, Formal analysis, Visualization, Data curation, Writing – review & editing. TH: Writing – review & editing, Formal analysis. TC: Project administration, Methodology, Writing – review & editing, Investigation. JH: Writing – review & editing, Project administration, Investigation. CP: Writing – review & editing, Funding acquisition, Resources, Methodology, Investigation, Conceptualization. BK: Methodology, Conceptualization, Project administration, Investigation, Funding acquisition, Supervision, Writing – review & editing, Resources. TA: Conceptualization, Supervision, Writing – review & editing, Writing – original draft, Formal analysis, Visualization, Methodology.
Conflict of interest
GA-L consults for Fluence Inc. TC serves as a consultant for Transcend Therapeutics, which had no involvement in or influence on this study. CP serves/has served as a consultant and/or receives/received research support from Biohaven Pharmaceuticals, Ceruvia Lifesciences, Freedom Biosciences, Transcend Therapeutics, Nobilis Therapeutics, UCB BioPharma, Teva Pharmaceuticals, Lundbeck Therapeutics, and F-Prime Capital Partners. He owns equity in Alco Therapeutics, Mind Therapeutics, and Lucid/Care. He receives royalties and/or honoraria from Oxford University Press and Up-To-Date, and has filed patents on pathogenic antibodies in pediatric OCD and on psychedelic drug combinations and mechanisms, irrelevant to the current work. BK reports grants from the Yale Center for Clinical Investigation, the Heffter Foundation, and the Turnbull Family Foundation during the conduct of the study. Dr. BK owns equity and serves as a consultant for Transcend Therapeutics, which had no involvement in or influence on this study; no other relationships or activities that could appear to have influenced the submitted work were reported. All aforementioned entities had no involvement in or influence on the current work.
The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Author disclaimer
This work represents the opinions of the authors and not of the State of Connecticut or other funders.
References
- 1. Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. (2010) 15:53–63. doi: 10.1038/mp.2008.94 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Stein DJ, Costa DLC, Lochner C, Miguel EC, Reddy YCJ, Shavitt RG, et al. Obsessive–compulsive disorder. Nat Rev Dis Primers. (2019) 5:52. doi: 10.1038/s41572-019-0102-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharm. (2002) 5:181–91. doi: 10.1017/S1461145702002900 [DOI] [PubMed] [Google Scholar]
- 4. Swierkosz-Lenart K, Dos Santos JFA, Elowe J, Clair A-H, Bally JF, Riquier F, et al. Therapies for obsessive-compulsive disorder: Current state of the art and perspectives for approaching treatment-resistant patients. Front Psychiatry. (2023) 14:1065812. doi: 10.3389/fpsyt.2023.1065812 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB, American Psychiatric Association . Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. (2007) 164:5–53. [PubMed] [Google Scholar]
- 6. Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: A meta-analysis. J Clin Psychiatry. (2016) 77:e605–11. doi: 10.4088/JCP.14r09758 [DOI] [PubMed] [Google Scholar]
- 7. Halberstadt AL. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res. (2015) 277:99–120. doi: 10.1016/j.bbr.2014.07.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. (2020) 21:611–24. doi: 10.1038/s41583-020-0367-2 [DOI] [PubMed] [Google Scholar]
- 9. Johnson MW, Griffiths RR. Potential therapeutic effects of psilocybin. Neurotherapeutics. (2017) 14:734–40. doi: 10.1007/s13311-017-0542-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Nichols DE. Psychedelics. Pharmacol Rev. (2016) 68:264–355. doi: 10.1124/pr.115.011478 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. (2008) 22:603–20. doi: 10.1177/0269881108093587 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Haikazian S, Chen-Li DCJ, Johnson DE, Fancy F, Levinta A, Husain MI, et al. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Psychiatry Res. (2023) 329:115531. doi: 10.1016/j.psychres.2023.115531 [DOI] [PubMed] [Google Scholar]
- 13. Yu CL, Yang FC, Yang SN, Tseng PT, Stubbs B, Yeh TC, et al. Psilocybin for end-of-life anxiety symptoms: A systematic review and meta-analysis. Psychiatry Investig. (2021) 18:958–67. doi: 10.30773/pi.2021.0209 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Meshkat S, Malik G, Zeifman RJ, Swainson J, Balachandra K, Reichelt AC, et al. Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review. Neurosci Biobehav Rev. (2025) 173:106163. doi: 10.1016/j.neubiorev.2025.106163 [DOI] [PubMed] [Google Scholar]
- 15. Kelmendi B, Adams T, Ching THW, Grazioplene R, Kichuk S, Fram G, et al. Psilocybin for treatment-resistant OCD: A randomized controlled trial. In: Psyarxiv. Charlottesville, Virginia: Center for Open Science (OSF/PsyArXiv) (2026). doi: 10.31234/osf.io/atfum_v1 [DOI] [Google Scholar]
- 16. Moreno FA, Allen KE, Wiegand CB, Dunne R, Prickett JI, Bayze B, et al. A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive–compulsive disorder. J Psychopharmacol. 40:02698811261424214. doi: 10.1177/02698811261424214 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Doss MK, Považan M, Rosenberg MD, Sepeda ND, Davis AK, Finan PH, et al. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry. (2021) 11:574. doi: 10.1038/s41398-021-01706-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Sayalı C, Truesdale A, Rosen DS, Barrett FS. Cognitive control as a transdiagnostic mechanism of action in psychedelic effects. Cognit Affect Behav Neurosci. (2026) 26:1–15. doi: 10.3758/s13415-025-01362-5 [DOI] [PubMed] [Google Scholar]
- 19. Ali SS, Carhart-Harris RL, Sieg KG. Classic psychedelics in obsessive–compulsive disorder: a circuit-based framework. Nat Ment Health. (2026) 4:540–50. doi: 10.1038/s44220-026-00626-437880705 [DOI] [Google Scholar]
- 20. Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci USA. (2012) 109:2138–43. doi: 10.1073/pnas.1119598109 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Gattuso JJ, Perkins D, Ruffell S, Lawrence AJ, Hoyer D, Jacobson LH, et al. Default mode network modulation by psychedelics: A systematic review. Int J Neuropsychopharmacol. (2023) 26:155–88. doi: 10.1093/ijnp/pyac074 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Koch K, Reeß TJ, Rus OG, Gürsel DA, Wagner G, Berberich G, et al. Increased default mode network connectivity in obsessive–compulsive disorder during reward processing. Front Psychiatry. (2018) 9:254. doi: 10.3389/fpsyt.2018.00254 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Beucke JC, Sepulcre J, Eldaief MC, Sebold M, Kathmann N, Kaufmann C. Default mode network subsystem alterations in obsessive–compulsive disorder. Br J Psychiatry. (2014) 205:376–82. doi: 10.1192/bjp.bp.113.137380 [DOI] [PubMed] [Google Scholar]
- 24. Stern ER, Fitzgerald KD, Welsh RC, Abelson JL, Taylor SF. Resting-state functional connectivity between fronto-parietal and default mode networks in obsessive-compulsive disorder. PloS One. (2012) 7:e36356. doi: 10.1371/journal.pone.0036356 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Letheby C, Gerrans P. Self unbound: ego dissolution in psychedelic experience. Neurosci Conscious. (2017) 2017. doi: 10.1093/nc/nix016 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Barrett FS, Johnson MW, Griffiths RR. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol. (2015) 29:1182–90. doi: 10.1177/0269881115609019 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Knowles KA, Olatunji BO. Intolerance of uncertainty as a cognitive vulnerability for obsessive-compulsive disorder: A qualitative review. Clin Psychol: Sci Pract. (2023) 30:317–30. doi: 10.1037/cps0000150 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Obsessive Compulsive Cognitions Working Group . Psychometric validation of the obsessive belief questionnaire and interpretation of intrusions inventory—Part 2: Factor analyses and testing of a brief version. Behav Res Ther. (2005) 43:1527–42. doi: 10.1016/j.brat.2004.07.010 [DOI] [PubMed] [Google Scholar]
- 29. Romeo B, Kervadec E, Fauvel B, Strika-Bruneau L, Amirouche A, Bezo A, et al. The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis. Neurosci Biobehav Rev. (2025) 172:106086. doi: 10.1016/j.neubiorev.2025.106086 [DOI] [PubMed] [Google Scholar]
- 30. Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. (2016) 30:1181–93. doi: 10.1177/0269881116675513 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. (2016) 30:1165–80. doi: 10.1177/0269881116675512 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Garcia-Romeu A, Griffiths R, Johnson M. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. CDAR. (2015) 7:157–64. doi: 10.2174/1874473708666150107121331 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol. (2018) 8:974. doi: 10.3389/fphar.2017.00974 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Barrett FS, Bradstreet MP, Leoutsakos JMS, Johnson MW, Griffiths RR. The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol. (2016) 30:1279–95. doi: 10.1177/0269881116678781 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Gashi L, Sandberg S, Pedersen W. Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences. Int J Drug Policy. (2021) 87:102997. doi: 10.1016/j.drugpo.2020.102997 [DOI] [PubMed] [Google Scholar]
- 36. Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol. (2016) 30:1268–78. doi: 10.1177/0269881116662634 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Wood MJ, McAlpine RG, Kamboj SK. Strategies for resolving challenging psychedelic experiences: insights from a mixed-methods study. Sci Rep. (2024) 14:28817. doi: 10.1038/s41598-024-79931-w [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Goodman WK. The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. Arch Gen Psychiatry. (1989) 46:1006. doi: 10.1001/archpsyc.1989.01810110048007 [DOI] [PubMed] [Google Scholar]
- 39. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Method. (1995) 57:289–300. doi: 10.1111/j.2517-6161.1995.tb02031.x40046247 [DOI] [Google Scholar]
- 40. Long JA. Jtools: Analysis and Presentation of Social Scientific Data. Available online at: https://cran.r-project.org/package=jtools (Accessed January 5, 2026).
- 41. Lüdecke D. sjPlot - data visualization for statistics in social science. doi: 10.5281/ZENODO.1308157 [DOI] [Google Scholar]
- 42. Robinson D, Alex Hayes. Couch Simons . Broom: Convert Statistical Objects Into Tidy Tibbles. Available online at: https://CRAN.R-project.org/package=broom (Accessed January 5, 2026).
- 43. McCulloch DEW, Grzywacz MZ, Madsen MK, Jensen PS, Ozenne B, Armand S, et al. Psilocybin-induced mystical-type experiences are related to persisting positive effects: A quantitative and qualitative report. Front Pharmacol. (2022) 13:841648. doi: 10.3389/fphar.2022.841648 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Carhart-Harris RL, Friston KJ. REBUS and the Anarchic Brain: Toward a unified model of the brain action of psychedelics. Pharmacol Rev. (2019) 71:316–44. doi: 10.1124/pr.118.017160 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Wood MJ, McAlpine RG, Kamboj SK. Strategies for resolving challenging psychedelic experiences: insights from a mixed-methods study. Sci Rep. (2024) 14:28817. doi: 10.1038/s41598-024-79931-w [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Ching THW, Stahnke B, Shnayder S, Agin-Liebes G, Adams TG Jr, Amoroso L, et al. Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis. Front Psychiatry. (2025) 16:1726818. doi: 10.3389/fpsyt.2025.1726818 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Obsessive Compulsive Cognitions Working Group . Development and initial validation of the obsessive beliefs questionnaire and the interpretation of intrusions inventory. Behav Res Ther. (2001) 39:987–1006. doi: 10.1016/S0005-7967(00)00085-1 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The datasets presented in this article are not readily available due to ethical and privacy considerations related to the small sample size and sensitive clinical content. De-identified data may be made available from the corresponding author upon reasonable request and with appropriate approvals.
